The International Institute for Drug Development (ID2) was established in Brussels (Belgium) in 1991 by Marc Buyse ScD.
The International Institute for Drug Development (ID2) was established in Brussels (Belgium) in 1991 by Marc Buyse ScD. With over 27 years of experience, IDDI is a valuable partner in the design, conduct and analysis in clinical research through optimal study design, innovative statistical methodology and state-of-the-art integrated web systems that help achieve time savings and cost-effective clinical trial processes.
The company expanded its client base in France and opened an office in Paris to ensure proximity to its French clients.
The company was renamed IDDI, International Drug Development Institute. An office was opened in Cambridge, Massachusetts, to offer advanced web-based services for clinical research supported by a dedicated help desk to cover the American time zones. Business development and Finance still operate out of Cambridge, MA to serve IDDI’s American clients.
Closed Paris office and consolidated European team in Belgium.
Moved headquarter to Louvain-la-Neuve.
IDDI opened a new office in Houston Texas. Operational team in the US.
Creation of a new branch, CluePoints, dedicated to Central Statistical Monitoring applied to clinical trials.
Revamp of IDDI Logo and strategy based on the three pillars of the company: PEOPLE, METHODOLOGY and TECHNOLOGY.
IDDI opens a new office in Raleigh in October 2014 and provides Data Management, Biostatistics and Project Management staff to serve US based clients.
IDDI extends its shareholding. SRIW (Société Régionale d’Investissement de Wallonie) takes 20% equity stake and IDDI management’s stake increases to 30%. This evolution is a major milestone for the company perennity and development.
IDDI – in partnership with Bristol Myers Squibb, the EORTC, the UCL, the University Hospital and Cancer Center of Lyon and with the financial support of the Walloon Region, Biowin – will develop a new statistical methodology (Generalised Pairwise Comparisons – GPC). GPC method will be further develop to usefully complement traditional methods for the design, analysis and interpretation of clinical-trial results and dedicated softwares will be developed as well.